Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Лечение гастроэзофагеальной рефлюксной болезни в свете последних рекомендаций. Место ингибиторов протонной помпы
Лечение гастроэзофагеальной рефлюксной болезни в свете последних рекомендаций. Место ингибиторов протонной помпы
М.В.Пчелинцев. Лечение гастроэзофагеальной рефлюксной болезни в свете последних рекомендаций. Место ингибиторов протонной помпы. Consilium Medicum. Гастроэнтерология (Прил.). 2014; 1: 5-10.
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Полный текст
Список литературы
1. Лазебник Л.Б., Машарова А.А., Бордин Д.С. и др. Результаты многоцентрового исследования «Эпидемиология гастроэзофагеальной рефлюксной болезни в России» (МЭГРЕ). Терапевт. арх. 2011; 1: 45–50.
2. Минушкин О.Н., Масловский Л.В., Теплухина О.Ю., Аникина Н.Ю. Гастроэзофагеальная рефлюксная болезнь: эпидемиологические, патогенетические, клинико-диагностические и терапевтические аспекты. Cons. Med. 2006; 2: 31–7.
3. Bell NJV, Burget D, Howden CW et al. Appropriate acid suppression for the management of gastro-oesophageal reflux disease. Digestion 1992; 51 (Suppl. 1): 59–67.
4. Ивашкин В.Т., Трухманов А.С. Гастроэзофагеальная рефлюксная болезнь. В кн.: Болезни пищевода. М., Триада-Х, 2000; с. 56–68.
5. Katz PO, Gerson LB, Vela MF. Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease. Am J Gastroenterol 2013; 108: 308–28.
6. Lundell L, Dent J, Bennett J et al. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut 1999; 45: 172–80.
7. Tytgat GN, McColl K, Tack J et al. New algorithm for the treatment of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2008; 27 (3): 249–56.
8. Malfertheiner P, Megraud F et al. Management of Helicobacter pylori infection – Maastricht IV/Florenct Consensus Report. Gut 2012; 61: 646–64.
9. Gerson LB, McMahon D, Olkin I et al. Lack of significant interactions between clopidogrel and proton pump inhibitor therapy: meta-analysis of existing literature. Dig Dis Sci 2012; 57: 1304–13.
10. Kwok CS et al. No consistent evidence of differential cardiovascular risk amongst proton pump inhibitor when used with clopidogrel: meta-analysis. Int J Cardiol 2013.
11. Chen M et al. A meta-analysis of impact of proton pump inhibitors on antiplatelet effect of clopidogrel. Cardiovasc Ther 2012; 30: 227–33.
12. Chen J et al. Pharmacodynamic Impacts of Proton Pump Inhibitor on the Efficacy of Clopidogrel in Vivo – A Systematic Review. Clin Cardiol 2013; 36 (4): 184–9.
13. Abelo A, Andersson TB, Bredberg E et al. Stereo selective metabolism by human liver CYP enzymes of a substituted benzimidazole. Drug Metab Dispos 2000; 28: 58–64.
14. Andersson Т, Rohss K, Hassan-Alin M, Bredberg E. Pharmacokinetic sand dose-response relationship of esomeprasole. Gastroenterology 2000; 118: A1210.
15. Rohss K, Hasselgren G, Hedenstrom H. Effect of esomeprazole 40 mg vs omeprazole 40 mg on 24-hour intragastric pH in patients with symptoms of gastroesophageal reflux disease. Dig Dis Sci 2002; 47: 954–8.
16. Wilder-Smith C, Rohss K, Lundin C, Rydholm H. Esomeprazole 40 mg provides more effective acid control than pantoprazole 40 mg. Gastroenterology 2000; 118: A22.
17. Richter J, Kahrilas P, Johanson J et al. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive oesophagitis: a randomized controlled trial. Am J Gastroenterol 2001; 96: 656–65.
18. Kahrilas P, Falk J, Johnson D et al. Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial. Aliment Pharmacol Ther 2000; 14: 1249–58.
19. Castell D, Castell D, Kahrilas P et al. Esomeprazole provides more effective healing than lansoprazole in GERD patients with erosive esophagitis. Gut 2001; 49 (Suppl. III): A3363.
20. Castell DO, Kahrilas PJ, Richter JE et al. Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive oesophagitis. Am J Gastroenterol 2002; 97: 575–83.
21. Vakil NB, Shaker R, Johnson DA et al. The new proton pump inhibitors omeprazole is effective as a maintanence therapy in GERD patients with healed erosive eosophagitis: a 6-month, randomized, double-blind, placebo-controlled study of efficacy and safety. Aliment Pharmacol Ther 2001; 15: 927–35.
22. Johnson D, Benjamin S, Vakil N et al. Esomeprazole once daily for 6 months is effective therapy for maintaining healed erosive eosophagitis and for controlling gastroesophageal reflux disease symptoms: a randomized, double-blind, placebo-controlled study of efficacy and safety. Am J Gastroenterol 2001; 96: 27–34.
23. Edwards SJ, Lind T, Lundell L. Systematic review of proton pump inhibitors for the acute treatment of reflux eosophagitis. Aliment Pharmacol Ther 2001; 15: 1729–36.
24. Edwards SJ, Lind T, Lundell L. Systematic review: proton pump inhibitors (PPIs) for the healing of reflux eosophagitis – a comparison with over PPIs. Aliment Pharmacol Ther 2006; 24: 743–50.
2. Минушкин О.Н., Масловский Л.В., Теплухина О.Ю., Аникина Н.Ю. Гастроэзофагеальная рефлюксная болезнь: эпидемиологические, патогенетические, клинико-диагностические и терапевтические аспекты. Cons. Med. 2006; 2: 31–7.
3. Bell NJV, Burget D, Howden CW et al. Appropriate acid suppression for the management of gastro-oesophageal reflux disease. Digestion 1992; 51 (Suppl. 1): 59–67.
4. Ивашкин В.Т., Трухманов А.С. Гастроэзофагеальная рефлюксная болезнь. В кн.: Болезни пищевода. М., Триада-Х, 2000; с. 56–68.
5. Katz PO, Gerson LB, Vela MF. Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease. Am J Gastroenterol 2013; 108: 308–28.
6. Lundell L, Dent J, Bennett J et al. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut 1999; 45: 172–80.
7. Tytgat GN, McColl K, Tack J et al. New algorithm for the treatment of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2008; 27 (3): 249–56.
8. Malfertheiner P, Megraud F et al. Management of Helicobacter pylori infection – Maastricht IV/Florenct Consensus Report. Gut 2012; 61: 646–64.
9. Gerson LB, McMahon D, Olkin I et al. Lack of significant interactions between clopidogrel and proton pump inhibitor therapy: meta-analysis of existing literature. Dig Dis Sci 2012; 57: 1304–13.
10. Kwok CS et al. No consistent evidence of differential cardiovascular risk amongst proton pump inhibitor when used with clopidogrel: meta-analysis. Int J Cardiol 2013.
11. Chen M et al. A meta-analysis of impact of proton pump inhibitors on antiplatelet effect of clopidogrel. Cardiovasc Ther 2012; 30: 227–33.
12. Chen J et al. Pharmacodynamic Impacts of Proton Pump Inhibitor on the Efficacy of Clopidogrel in Vivo – A Systematic Review. Clin Cardiol 2013; 36 (4): 184–9.
13. Abelo A, Andersson TB, Bredberg E et al. Stereo selective metabolism by human liver CYP enzymes of a substituted benzimidazole. Drug Metab Dispos 2000; 28: 58–64.
14. Andersson Т, Rohss K, Hassan-Alin M, Bredberg E. Pharmacokinetic sand dose-response relationship of esomeprasole. Gastroenterology 2000; 118: A1210.
15. Rohss K, Hasselgren G, Hedenstrom H. Effect of esomeprazole 40 mg vs omeprazole 40 mg on 24-hour intragastric pH in patients with symptoms of gastroesophageal reflux disease. Dig Dis Sci 2002; 47: 954–8.
16. Wilder-Smith C, Rohss K, Lundin C, Rydholm H. Esomeprazole 40 mg provides more effective acid control than pantoprazole 40 mg. Gastroenterology 2000; 118: A22.
17. Richter J, Kahrilas P, Johanson J et al. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive oesophagitis: a randomized controlled trial. Am J Gastroenterol 2001; 96: 656–65.
18. Kahrilas P, Falk J, Johnson D et al. Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial. Aliment Pharmacol Ther 2000; 14: 1249–58.
19. Castell D, Castell D, Kahrilas P et al. Esomeprazole provides more effective healing than lansoprazole in GERD patients with erosive esophagitis. Gut 2001; 49 (Suppl. III): A3363.
20. Castell DO, Kahrilas PJ, Richter JE et al. Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive oesophagitis. Am J Gastroenterol 2002; 97: 575–83.
21. Vakil NB, Shaker R, Johnson DA et al. The new proton pump inhibitors omeprazole is effective as a maintanence therapy in GERD patients with healed erosive eosophagitis: a 6-month, randomized, double-blind, placebo-controlled study of efficacy and safety. Aliment Pharmacol Ther 2001; 15: 927–35.
22. Johnson D, Benjamin S, Vakil N et al. Esomeprazole once daily for 6 months is effective therapy for maintaining healed erosive eosophagitis and for controlling gastroesophageal reflux disease symptoms: a randomized, double-blind, placebo-controlled study of efficacy and safety. Am J Gastroenterol 2001; 96: 27–34.
23. Edwards SJ, Lind T, Lundell L. Systematic review of proton pump inhibitors for the acute treatment of reflux eosophagitis. Aliment Pharmacol Ther 2001; 15: 1729–36.
24. Edwards SJ, Lind T, Lundell L. Systematic review: proton pump inhibitors (PPIs) for the healing of reflux eosophagitis – a comparison with over PPIs. Aliment Pharmacol Ther 2006; 24: 743–50.
Авторы
М.В.Пчелинцев
ГБОУ ВПО Первый Санкт-Петербургский государственный медицинский университет им. И.П.Павлова Минздрава России
ГБОУ ВПО Первый Санкт-Петербургский государственный медицинский университет им. И.П.Павлова Минздрава России
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.